Antibody-Drug Conjugates (ADCs) are a new generation of highly potent therapeutic molecules which have the potential to revolutionize cancer therapy in the next few years in terms of efficiency and tolerability. These molecules feature improved cancer cell-killing properties by targeting tumors more accurately and specifically. They also have an extended lifetime within the bloodstream and put the therapeutic margin of safety to a higher grade, which dramatically decreases the adverse effects of chemotherapy and improves patient welfare during the treatment.

What are ADCs made of?

ADCs are a combination of biological and chemical components which all have a specific role in the stability and effectiveness of the whole molecule. Optimization of each one is the key for a specific treatment protocol to succeed. Read more about ADCs.

How do ADCs work?

ADCs combine the specific binding capacity of monoclonal antibodies and the highly cytotoxic effects of last generation bioactive molecules. Read more about cancer therapy using ADCs.

Mablink Technology

Our patented and innovative drug-linker platform technology has made it possible to address many well known antibody-drug coupling limitations. Every step of the reaction has been optimized so that the technology can be quickly implemented onto any preexisting monoclonal antibody, thus providing improved physicochemical and pharmacological properties to your ADCs. Read more about Mablink technology.